Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

A new cheaper biosimilar version of Sanofi's Lantus (insulin glargine) has been launched in the UK today, and is likely to dent sales of the blockbuster product. Lilly and Boehringer Ingelheim's ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...

Eli Lilly is far from a pure-play ... Its leading drugs include Lantus for diabetes management and Dupixent for treating atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps.

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly (NYSE: LLY). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom.

Learn More » Patients self-administer, through injection, the Novo Nordisk and Lilly drugs, and they do this on a weekly basis. The pharma giants aren't stopping there, though. The next big ...